AI Startups
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The biotech unicorn aims to revolutionize clinical trials by mapping the chemistry of nature with machine learning.
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
TA
TechCrunch AI
Source
TechCrunch AI
AI Analysis
Generated insight by OnAirToday AI
Enveda's massive funding round highlights the growing synergy between natural product chemistry and generative AI for rapid drug discovery. By unlocking biological secrets hidden in nature, the company is bridging the gap between traditional medicine and accelerated pharmaceutical innovation.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Filed under:AI Startups
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.